RESUMO
A novel virus-imprinted polymer for prevention of viral infection was prepared by anchoring molecularly imprinted polymer (MIP) on the surface of poly-dopamine (PDA)-coated silica particles. The imprinting reaction was carried out via self-polymerization of dopamine in the presence of a virus template. Plaque forming assay indicated that the MIP exhibited selective anti-viral infection properties for the template virus in complex media containing different interfering substances, and even other types of viruses. Remarkable dose-dependent and time-dependent inhibition of virus infection was observed due to the MIP's selective binding to the template virus. When the MIP was incubated with the virus and host cells together, rapid and selective adsorption of template viruses by the MIP prevented the viruses to infect the host cells in a period of 12h. The MIP was biocompatible and non-toxic, and had excellent stability and reusability. Furthermore, the MIPs prepared using different viruses as templates showed similar anti-viral infection properties. The MIP synthesized using dopamine as monomer and crude virus as template provided an attractive possibility for clinical applications in the field of antiviral therapy. STATEMENT OF SIGNIFICANCE: This is the first report to prepare artificial antibody (molecularly imprinted polymer, MIP) that can selectively prevent virus infection using dopamine self-polymerization system. Only MIP anchoring on the surface of poly-dopamine coated silica particles and polymerized using ammonium persulfate as radical initiator showed dose-dependent and time-dependent inhibition of template virus infection in complex media containing interferences and even other viruses. Viruses bond to MIP lost infectious capability. When incubated with virus and host cells, MIP rebond viruses rapidly and selectively to prevent viruses infecting host cells for 12h. The achieved MIPs were biocompatibility, non-toxicity with excellent stability and reusability, and can be used to different viruses. The bio-mimic MIPs provided an attractive prospect for clinical applications in antiviral therapy.